These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21691126)

  • 1. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.
    Meijer E; Boertien WE; Zietse R; Gansevoort RT
    Kidney Blood Press Res; 2011; 34(4):235-44. PubMed ID: 21691126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case for water in the treatment of polycystic kidney disease.
    Torres VE; Bankir L; Grantham JJ
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1140-50. PubMed ID: 19443627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
    Ecder T; Schrier RW
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):369-74. PubMed ID: 15151483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives.
    Clark WF; Devuyst O; Roussel R
    J Intern Med; 2017 Oct; 282(4):310-321. PubMed ID: 28905441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autosomal dominant polycystic kidney disease: time for a change?
    Chapman AB
    J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin antagonists in polycystic kidney disease.
    Torres VE
    Semin Nephrol; 2008 May; 28(3):306-17. PubMed ID: 18519091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
    Chang MY; Parker E; El Nahas M; Haylor JL; Ong AC
    J Am Soc Nephrol; 2007 Feb; 18(2):560-9. PubMed ID: 17202412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
    Lawson CR; Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
    Meijer E; Gansevoort RT; de Jong PE; van der Wal AM; Leonhard WN; de Krey SR; van den Born J; Mulder GM; van Goor H; Struck J; de Heer E; Peters DJ
    Nephrol Dial Transplant; 2011 Aug; 26(8):2445-53. PubMed ID: 21393612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic Kidney Disease and the Vasopressin Pathway.
    van Gastel MDA; Torres VE
    Ann Nutr Metab; 2017; 70 Suppl 1():43-50. PubMed ID: 28614813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible involvement of vasopressin and urine concentrating process in the progression of chronic renal failure.
    Bankir L; Bouby N; Trinh-Trang-Tan MM
    Kidney Int Suppl; 1989 Nov; 27():S32-7. PubMed ID: 2700000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modern treatment of autosomal dominant polycystic kidney disease].
    Wołyniec W; Jankowska MM; Rutkowski B
    Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopressin beyond water: implications for renal diseases.
    Bolignano D; Zoccali C
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):499-504. PubMed ID: 20689424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.
    Grantham JJ; Chapman AB; Torres VE
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):148-57. PubMed ID: 17699202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoregulation of renal blood flow and pressure-dependent renin release in autosomal dominant polycystic kidney disease of rats.
    Braun C; Lüdicke C; Rebsch W; Gretz N; van der Woude FJ; Rohmeiss P
    Nephrol Dial Transplant; 1996; 11 Suppl 6():52-7. PubMed ID: 9044329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
    Torres VE; Wang X; Qian Q; Somlo S; Harris PC; Gattone VH
    Nat Med; 2004 Apr; 10(4):363-4. PubMed ID: 14991049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydration and Chronic Kidney Disease Progression: A Critical Review of the Evidence.
    Clark WF; Sontrop JM; Huang SH; Moist L; Bouby N; Bankir L
    Am J Nephrol; 2016; 43(4):281-92. PubMed ID: 27161565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for polycystic kidney disease? It's water, stupid!
    Grantham JJ
    J Am Soc Nephrol; 2008 Jan; 19(1):1-7. PubMed ID: 18032792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.